Well, the plot thickens.
Valeant in mid Dec bought the division that has Retin a from J&J for about $400 mill.
The following is based on the assumption that the cosmetics partner is j&j.
Have j&j been formulating a product to compete with this product in their now sold division?
From what I gather it is predominantly a prescription product. Thus doesn't match the mass market formula.
But it doesn't mean a mass market product with TPM is not better than the prescription product. Less active thus not requiring a prescription and better effect even from the lower dose. Remember the prime problem is with irritation.
J&j having their new product fully funded by selling the superceded product and keeping the competition watchdogs happy.
Looks like an elegant business solution.
- Forums
- ASX - By Stock
- j & j eats itself
Well, the plot thickens.Valeant in mid Dec bought the division...
-
-
- There are more pages in this discussion • 118 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AVE (ASX) to my watchlist
|
|||||
Last
0.3¢ |
Change
0.001(20.0%) |
Mkt cap ! $9.507M |
Open | High | Low | Value | Volume |
0.3¢ | 0.3¢ | 0.3¢ | $1.366K | 455.7K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
60 | 99145902 | 0.2¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
0.3¢ | 22467224 | 7 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
60 | 99145902 | 0.002 |
20 | 74250508 | 0.001 |
0 | 0 | 0.000 |
0 | 0 | 0.000 |
0 | 0 | 0.000 |
Price($) | Vol. | No. |
---|---|---|
0.003 | 22467224 | 7 |
0.004 | 24316867 | 21 |
0.005 | 27709765 | 14 |
0.006 | 19365067 | 10 |
0.007 | 9365221 | 8 |
Last trade - 16.10pm 09/07/2024 (20 minute delay) ? |
Featured News
AVE (ASX) Chart |